Drugs / 9vHPV
9vHPV
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05372016 | Sep 2020 → Jun 2022 | adenocarcinoma in situ, anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia grade 2/3 +2 | Shanghai Bovax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01651949 | Oct 2012 → Aug 2014 | anal carcinoma, anogenital human papillomavirus infection, intraepithelial neoplasia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9vHPV | “9vHPV vaccine ,0.5mL, three doses, 0,2,6 months” NCT05372016 ↗ |
| Known as | 9-valent HPV vaccine | “This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.” NCT01651949 ↗ |
| Known as | V503 | “9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen” NCT01651949 ↗ |
| Modality | Vaccine | “a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine” NCT01651949 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection” NCT01651949 ↗ |